CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 177 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $141 | +442.3% | 4,742 | +225.5% | 0.00% | – |
| Q2 2023 | $26 | +13.0% | 1,457 | 0.0% | 0.00% | – |
| Q1 2023 | $23 | -14.8% | 1,457 | 0.0% | 0.00% | – |
| Q4 2022 | $27 | -99.9% | 1,457 | 0.0% | 0.00% | – |
| Q3 2022 | $29,000 | +7.4% | 1,457 | 0.0% | 0.00% | – |
| Q2 2022 | $27,000 | -20.6% | 1,457 | 0.0% | 0.00% | – |
| Q1 2022 | $34,000 | -17.1% | 1,457 | 0.0% | 0.00% | – |
| Q4 2021 | $41,000 | +32.3% | 1,457 | 0.0% | 0.00% | – |
| Q3 2021 | $31,000 | +14.8% | 1,457 | 0.0% | 0.00% | – |
| Q2 2021 | $27,000 | -15.6% | 1,457 | -36.4% | 0.00% | – |
| Q4 2020 | $32,000 | -11.1% | 2,292 | 0.0% | 0.00% | – |
| Q3 2020 | $36,000 | -10.0% | 2,292 | 0.0% | 0.00% | – |
| Q2 2020 | $40,000 | +566.7% | 2,292 | +403.7% | 0.00% | – |
| Q1 2020 | $6,000 | -45.5% | 455 | 0.0% | 0.00% | – |
| Q4 2019 | $11,000 | -47.6% | 455 | -47.0% | 0.00% | – |
| Q2 2019 | $21,000 | – | 858 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
| First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
| Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
| Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
| Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
| 5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
| MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
| Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
| Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |